DE69820449T2 - T-zell-membranprotein (tirc7), davon abgeleitete peptide und antikörper und ihre verwendungen - Google Patents

T-zell-membranprotein (tirc7), davon abgeleitete peptide und antikörper und ihre verwendungen Download PDF

Info

Publication number
DE69820449T2
DE69820449T2 DE69820449T DE69820449T DE69820449T2 DE 69820449 T2 DE69820449 T2 DE 69820449T2 DE 69820449 T DE69820449 T DE 69820449T DE 69820449 T DE69820449 T DE 69820449T DE 69820449 T2 DE69820449 T2 DE 69820449T2
Authority
DE
Germany
Prior art keywords
cell
tirc7
protein
antibody
membrane protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69820449T
Other languages
German (de)
English (en)
Other versions
DE69820449D1 (de
Inventor
Nalan Utku
R. Steven GULLANS
L. Edgar MILFORD
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Utku Nalan Dr 10719 Berlin De
Brigham and Womens Hospital Inc
Original Assignee
Utku Nalan Dr
Brigham and Womens Hospital Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE19738710A external-priority patent/DE19738710A1/de
Application filed by Utku Nalan Dr, Brigham and Womens Hospital Inc filed Critical Utku Nalan Dr
Priority to DE69820449T priority Critical patent/DE69820449T2/de
Application granted granted Critical
Publication of DE69820449D1 publication Critical patent/DE69820449D1/de
Publication of DE69820449T2 publication Critical patent/DE69820449T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Transplantation (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
DE69820449T 1997-08-29 1998-08-28 T-zell-membranprotein (tirc7), davon abgeleitete peptide und antikörper und ihre verwendungen Expired - Lifetime DE69820449T2 (de)

Priority Applications (1)

Application Number Priority Date Filing Date Title
DE69820449T DE69820449T2 (de) 1997-08-29 1998-08-28 T-zell-membranprotein (tirc7), davon abgeleitete peptide und antikörper und ihre verwendungen

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
DE19738710 1997-08-29
DE19738710A DE19738710A1 (de) 1997-08-29 1997-08-29 Verwendung von TIRC7 zur Herstellung von Mitteln zur Inhibition der Immunantwort
DE29802653U 1998-02-12
DE29802653 1998-02-12
PCT/EP1998/005462 WO1999011782A1 (en) 1997-08-29 1998-08-28 T-cell membrane protein (tirc7), peptides and antibodies derived therefrom and uses thereof
DE69820449T DE69820449T2 (de) 1997-08-29 1998-08-28 T-zell-membranprotein (tirc7), davon abgeleitete peptide und antikörper und ihre verwendungen

Publications (2)

Publication Number Publication Date
DE69820449D1 DE69820449D1 (de) 2004-01-22
DE69820449T2 true DE69820449T2 (de) 2005-03-10

Family

ID=26039678

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69820449T Expired - Lifetime DE69820449T2 (de) 1997-08-29 1998-08-28 T-zell-membranprotein (tirc7), davon abgeleitete peptide und antikörper und ihre verwendungen

Country Status (10)

Country Link
EP (2) EP0996726B1 (enExample)
JP (1) JP4459435B2 (enExample)
AT (1) ATE256185T1 (enExample)
AU (1) AU751151C (enExample)
CA (1) CA2301499C (enExample)
DE (1) DE69820449T2 (enExample)
DK (1) DK0996726T3 (enExample)
ES (1) ES2213295T3 (enExample)
PT (1) PT996726E (enExample)
WO (1) WO1999011782A1 (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL134830A0 (en) * 2000-03-01 2001-05-20 Chay 13 Medical Res Group N V Peptides and immunostimulatory and anti-bacterial pharmaceutical compositions containing them
AU2001263888A1 (en) * 2000-05-03 2001-11-12 Genpat77 Pharmacogenetics Ag Uses of tgap7 for the modulation of leucocyte activation
US20040072780A1 (en) * 2000-10-30 2004-04-15 Nalan Utku Methods for obtaining inhibitors of tirc7 ligand binding and uses thereof
US6905827B2 (en) 2001-06-08 2005-06-14 Expression Diagnostics, Inc. Methods and compositions for diagnosing or monitoring auto immune and chronic inflammatory diseases
US7026121B1 (en) 2001-06-08 2006-04-11 Expression Diagnostics, Inc. Methods and compositions for diagnosing and monitoring transplant rejection
US20050048067A1 (en) * 2001-09-17 2005-03-03 Nalan Utku Peptides capable of modulating immune response
EP1448227A2 (en) * 2001-11-27 2004-08-25 GenPat77 Pharmacogenetics AG Use of t-cell immune response cdna 7 (tirc7) for modulation of angiogenesis and/or neovascularization
EP1492817A2 (en) * 2001-12-21 2005-01-05 GenPat77 Pharmacogenetics AG Therapeutic monoclonal anti-tirc7 antibodies for use in immune related and other diseases
JP2005531282A (ja) 2001-12-21 2005-10-20 ゲンパト７７ ファーマコジェネティクス エージー 炎症性疾患の治療に用いる抗ｔｉｒｃ７抗体
EP1492555A2 (en) * 2002-02-04 2005-01-05 Nalan Utku Compositions and methods for modulation of effects on phagocyte and lymphoid cell population
US20050221424A1 (en) * 2002-04-26 2005-10-06 Nalan Utku Bispecific molecules for use in therapy and diagnosis of immune related and other diseases
WO2003093318A1 (en) * 2002-04-29 2003-11-13 Genpat77 Pharmacogenetics Ag Novel antibody binding tcr and tirc7 and its use in therapy and diagnosis
CN101268373A (zh) * 2005-05-17 2008-09-17 塞尔艾克特制药有限公司 作为检测早期免疫激活的标记物的tirc7
WO2006122792A1 (en) * 2005-05-17 2006-11-23 Genpat77 Pharmacogenetics Ag Peptides capable of modulating the function of tirc7
DE202011103324U1 (de) 2011-07-12 2012-01-02 Nekonal S.A.R.L. Therapeutische anti-TIRC7 Antikörper für die Verwendung in Immun und anderen Krankheiten
CA3033645A1 (en) 2016-08-09 2018-02-15 Nekonal S.A.R.L. Tirc7 based diagnostic and therapy of cancer
CA3033620A1 (en) 2016-08-10 2018-02-15 Nekonal S.A.R.L. Tirc7 based diagnostic and therapy of solid cancer
US20220288120A1 (en) 2019-08-14 2022-09-15 Nekonal S.A.R.L. Method for producing engineered tirc7 specific t-regulatory cells (tregs)

Also Published As

Publication number Publication date
ES2213295T3 (es) 2004-08-16
CA2301499C (en) 2010-01-26
WO1999011782A1 (en) 1999-03-11
EP1350848A3 (en) 2004-02-04
ATE256185T1 (de) 2003-12-15
EP0996726B1 (en) 2003-12-10
EP1350848A2 (en) 2003-10-08
PT996726E (pt) 2004-04-30
EP0996726A1 (en) 2000-05-03
AU751151C (en) 2006-09-14
JP2001514852A (ja) 2001-09-18
JP4459435B2 (ja) 2010-04-28
AU751151B2 (en) 2002-08-08
CA2301499A1 (en) 1999-03-11
DE69820449D1 (de) 2004-01-22
AU9265498A (en) 1999-03-22
DK0996726T3 (da) 2004-04-13

Similar Documents

Publication Publication Date Title
DE69820449T2 (de) T-zell-membranprotein (tirc7), davon abgeleitete peptide und antikörper und ihre verwendungen
DE60132699T2 (de) Nukleinsäuren und polypeptide, die sich auf b7 beziehen und ihre verwendungen zur immunmodulierung
DE69431797T2 (de) Verfahren und Stoffe zur Modulation der immunsuppressiven Aktivität und Toxitätvon monoklonalen Antikörpern
EP1017723B1 (de) Ko-stimulierendes polypeptid von t-zellen, monoklonale antikörper sowie die herstellung und deren verwendung
DE69535375T2 (de) Lösliche polypeptidfraktionen des lag-3-proteins; verfahren zur herstellung; therapeutische zusamensetzung; antiidiotypischer antikörper
DE69434465T2 (de) Verfahren zur Regulierung der Immunantwort durch den Gebrauch von CTLA4-Bindungsmolekülen und IL4-Bindungsmolekülen
DE69434738T2 (de) Ein FAS Ligand, ein Fragment davon und kodierende DNA dafür
DE69633617T2 (de) Il-17 receptor
DE69434908T2 (de) Rezeptor an der oberfläche von aktivierten t-zellen:act4
DE69636216T2 (de) Zusammensetzungen und verfahren zur behandlung und diagnose von immunstörungen
DE69624436T2 (de) Humaner 4-1bb spezifischer humaner antikörper und diesen produzierende zellinie
DE69322289T2 (de) Behandlung von entzündlichen darmerkrankungen mit interferon-gamma-inhibitoren
DE69226871T2 (de) CTL4A Rezeptor, ihn enthaltenden Fusionsproteine und deren Verwendungen
JP3703834B2 (ja) 活性化ｃｄ４▲上＋▼ｔ細胞の表層上のレセプターに対するリガンド（ａｃｔ−４−ｌ）
DE68928915T2 (de) Immunotherapie mit einbeziehung der cd28-stimulation
DE60035517T2 (de) Gl50 moleküle, sowie verwendungen derselben
DE69534962T3 (de) Htk-ligand
DE19821060A1 (de) Ko-stimulierendes Polypeptid von T-Zellen, monoklonale Antikörper sowie die Herstellung und deren Verwendung
DE69320336T2 (de) Isolierung, Charakterisierung und Verwendung der menschlichen Beta-Einheit des Immunglobulin E-Hochaffinitätsrezeptors
US7863418B2 (en) T-cell membrane protein (TIRC7) and peptides derived therefrom
EP2351840A1 (en) Polypeptides involved in immune response
DE69230762T2 (de) Icams konstante domäne wasserlöslichen fusionsproteine, immunoglobulin
DE69931926T2 (de) Immunologisches reagens, das spezifisch mit der extrazellulären domäne der menschlichen zeta-kette reagiert
DE69535690T2 (de) Kostimulatorisches T-Zell-Oberflächen-Antigen SLAM
DE60122721T2 (de) Diagnostische verwendungen des t-zell proteins tzon7, der davon abgeleiteten peptide und des antikörpers

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: THE BRIGHAM AND WOMEN'S HOSPITAL INC., BOSTON, MAS

Owner name: UTKU, NALAN, DR., 10719 BERLIN, DE

8328 Change in the person/name/address of the agent

Representative=s name: KOENIG SZYNKA TILMANN VON RENESSE, 40549 DUESSELDO